The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISAL 2019 | BCL-2 targeting in AML: updates
Marina Konopleva, MD, PhD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the latest updates in BCL-2 targeting for acute myeloid leukemia (AML) at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany. Prof. Konopleva highlights the importance of this therapy for elderly patients who cannot tolerate other therapies, while it also has the potential to be combined with more intensive treatments in younger patients.
